116 related articles for article (PubMed ID: 15578434)
1. Molecular pathology of low malignant bladder transitional cell carcinoma: a current perspective.
Wang HT; Chang JW
Histol Histopathol; 2005 Jan; 20(1):147-53. PubMed ID: 15578434
[TBL] [Abstract][Full Text] [Related]
2. Fibroblast growth factor receptor 3 is overexpressed in urinary tract carcinomas and modulates the neoplastic cell growth.
Gómez-Román JJ; Saenz P; Molina M; Cuevas González J; Escuredo K; Santa Cruz S; Junquera C; Simón L; Martínez A; Gutiérrez Baños JL; López-Brea M; Esparza C; Val-Bernal JF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):459-65. PubMed ID: 15701828
[TBL] [Abstract][Full Text] [Related]
3. [The clinico-pathological significance of protein expression of PAK1 in bladder transitional cell carcinoma].
Zhang YH; Xie D; Luo JH; Chen W; Chen LW; Xu QC; Liu GY; Ma HB; Lin WQ
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(38):2710-3. PubMed ID: 18167251
[TBL] [Abstract][Full Text] [Related]
4. [The clinical significance of expression and amplification of FGF3 in bladder transitional cell carcinoma].
Zhang YH; Xie D; Luo JH; Chen W; Chen LW; Xu QC
Zhonghua Yi Xue Za Zhi; 2006 Sep; 86(36):2556-9. PubMed ID: 17198565
[TBL] [Abstract][Full Text] [Related]
5. [DAB2IP expression in bladder transitional cell carcinoma and its correlation with clinical outcome].
Zhu JN; Wu KJ; Guan ZF; Liu LX; Ning ZY; Zhou JC; Wang XY; Fan JH
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):591-4. PubMed ID: 25286682
[TBL] [Abstract][Full Text] [Related]
6. [Recent advances in molecular pathology of bladder cancer].
Cheng L; Xu JW; Teng XD; Zhao J
Zhonghua Bing Li Xue Za Zhi; 2011 Nov; 40(11):779-82. PubMed ID: 22336167
[No Abstract] [Full Text] [Related]
7. Promoter hypermethylation of the 14-3-3 sigma, SYK and CAGE-1 genes is related to the various phenotypes of urinary bladder carcinomas and associated with progression of transitional cell carcinomas.
Kunze E; Wendt M; Schlott T
Int J Mol Med; 2006 Oct; 18(4):547-57. PubMed ID: 16964403
[TBL] [Abstract][Full Text] [Related]
8. [Smad4 and TGF-beta1 expression and clinical significance in bladder transitional cell carcinoma].
Tang ZY; Yang LY; Zhang YJ; Peng KL; Qi L
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Jun; 31(3):363-6. PubMed ID: 16859125
[TBL] [Abstract][Full Text] [Related]
9. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
Jebar AH; Hurst CD; Tomlinson DC; Johnston C; Taylor CF; Knowles MA
Oncogene; 2005 Aug; 24(33):5218-25. PubMed ID: 15897885
[TBL] [Abstract][Full Text] [Related]
10. The NOTCH pathway plays a tumor suppressive role in bladder cancer.
Cancer Discov; 2014 Nov; 4(11):1252. PubMed ID: 25367939
[TBL] [Abstract][Full Text] [Related]
11. [Differential expression of hyaluronic acid synthase family in human bladder transitional cell carcinoma and its clinical significance].
Cai JL; Li M; Na YQ
Zhonghua Zhong Liu Za Zhi; 2011 Feb; 33(2):121-5. PubMed ID: 21575480
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 expression in bladder transitional cell carcinoma and its relationship with clinicopathological features.
Li Y; Chen M; Yuan J; Zhou X; He W; Zu X; Qi L
Urol Int; 2014; 92(2):157-63. PubMed ID: 23988662
[TBL] [Abstract][Full Text] [Related]
13. Correlation of tumor relapse and elevated expression of survivin and vascular endothelial growth factor in superficial bladder transitional cell carcinoma.
Sun YW; Xuan Q; Shu QA; Wu SS; Chen H; Xiao J; Xiang P; Zhu YP; Wang FL; Zhao ST
Genet Mol Res; 2013 Apr; 12(2):1045-53. PubMed ID: 23613251
[TBL] [Abstract][Full Text] [Related]
14. Frequent FGFR3 mutations in urothelial papilloma.
van Rhijn BW; Montironi R; Zwarthoff EC; Jöbsis AC; van der Kwast TH
J Pathol; 2002 Oct; 198(2):245-51. PubMed ID: 12237885
[TBL] [Abstract][Full Text] [Related]
15. FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder.
Bakkar AA; Wallerand H; Radvanyi F; Lahaye JB; Pissard S; Lecerf L; Kouyoumdjian JC; Abbou CC; Pairon JC; Jaurand MC; Thiery JP; Chopin DK; de Medina SG
Cancer Res; 2003 Dec; 63(23):8108-12. PubMed ID: 14678961
[TBL] [Abstract][Full Text] [Related]
16. [The mRNA expression of platelet-derived endothelial cell growth factor of bladder transitional cell carcinoma and its relation to invasiveness].
Li G; Zhang YF; Ding Q; Wen DG; Yan CY
Zhonghua Zhong Liu Za Zhi; 2004 Jan; 26(1):30-2. PubMed ID: 15059350
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of Epidermal Growth Factor Receptor (EGFR) and HER-2 in Bladder Carcinoma and Its Association with Patients' Clinical Features.
Li W; Wang Y; Tan S; Rao Q; Zhu T; Huang G; Li Z; Liu G
Med Sci Monit; 2018 Oct; 24():7178-7185. PubMed ID: 30296252
[TBL] [Abstract][Full Text] [Related]
18. Effects of YC-1 on hypoxia-inducible factor 1 alpha in hypoxic human bladder transitional carcinoma cell line T24 cells.
Li Y; Zhao X; Tang H; Zhong Z; Zhang L; Xu R; Li S; Wang Y
Urol Int; 2012; 88(1):95-101. PubMed ID: 22041818
[TBL] [Abstract][Full Text] [Related]
19. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.
Sibley K; Cuthbert-Heavens D; Knowles MA
Oncogene; 2001 Feb; 20(6):686-91. PubMed ID: 11314002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
